Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy

[1]  M. Koch,et al.  Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy , 2014, BMC Cancer.

[2]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[3]  M. Gönen,et al.  Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. , 2012, Surgery.

[4]  M. Koch,et al.  Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. D'Angelica,et al.  CXCR4 Expression Predicts Patient Outcome and Recurrence Patterns after Hepatic Resection for Colorectal Liver Metastases , 2012, Annals of Surgical Oncology.

[6]  M. Koch,et al.  Invasion front‐specific expression and prognostic significance of microRNA in colorectal liver metastases , 2011, Cancer science.

[7]  M. Koch,et al.  The Predictive Value of Postoperative Clinical Risk Scores for Outcome After Hepatic Resection: A Validation Analysis in 807 Patients , 2011, Annals of Surgical Oncology.

[8]  M. Koch,et al.  Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases , 2011, Annals of Surgical Oncology.

[9]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Koch,et al.  Postoperative course and clinical significance of biochemical blood tests following hepatic resection , 2010, The British journal of surgery.

[11]  P. Colombo,et al.  Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases? , 2010, Annals of surgery.

[12]  M. Koch,et al.  Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. , 2010, Gastroenterology.

[13]  N. Kemeny,et al.  KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.

[14]  C. Bokemeyer,et al.  A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Koch,et al.  IVC CLAMP: infrahepatic inferior vena cava clamping during hepatectomy - a randomised controlled trial in an interdisciplinary setting , 2009, Trials.

[16]  W. Hohenberger,et al.  Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases , 2009, Journal of surgical oncology.

[17]  M. Koch,et al.  Validation of Prognostic Scoring Systems for Patients Undergoing Resection of Colorectal Cancer Liver Metastases , 2009, Annals of Surgical Oncology.

[18]  J. Budczies,et al.  A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. , 2009, Gastroenterology.

[19]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Leslie H. Sobin,et al.  Comprar TNM Classification of Malignant Tumours, 7th Edition | C. Wittekind | 9781444332414 | Wiley , 2009 .

[21]  M. Koch,et al.  Meta-Analysis of the Clamp-Crushing Technique for Transection of the Parenchyma in Elective Hepatic Resection: Back to Where We Started? , 2009, Annals of Surgical Oncology.

[22]  R. Labianca,et al.  Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Büchler,et al.  Systematic review and meta‐analysis of the effect of portal triad clamping on outcome after hepatic resection , 2008, The British journal of surgery.

[24]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[25]  Yuman Fong,et al.  Actual 10-year survival after resection of colorectal liver metastases defines cure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Donohue,et al.  Hepatic Resection for Colorectal Metastases: Value for Risk Scoring Systems? , 2007, Annals of surgery.

[27]  R. Parks,et al.  Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. , 2007, Journal of the American College of Surgeons.

[28]  J. Bosset,et al.  Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Gonen,et al.  Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases , 2006, Annals of Surgical Oncology.

[30]  C. Bokemeyer,et al.  Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[32]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[33]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[35]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[36]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  O. Bouché,et al.  Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Lotz,et al.  CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.

[39]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[40]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[41]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Marco Lorenzi,et al.  Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. , 1994, Gastroenterology.

[43]  J. Dierlamm,et al.  Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  A. Altendorf-Hofmann,et al.  Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history , 1990, The British journal of surgery.

[45]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[46]  M. O’connell,et al.  Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver. , 1985, Mayo Clinic proceedings.